🔗 Share this article

Given that the United States proceeds with unprecedented adjustments to its vaccination recommendations, an unexpected name has emerged somewhat surprisingly: Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by questioning Covid shots throughout the global health crisis and has focused upon potential fatalities following Covid vaccination in her short position at the US Food and Drug Administration (FDA).

Scheduled Changes to Pediatric Immunization Program

Agency leaders had intended to unveil radical changes to the pediatric vaccine schedule recently, bringing the US with the Danish immunization schedule, sources say – a substantial departure that would place the US at odds with many the global community with no evidence for improved outcomes. The announcement has been pushed back until the next year.

Rather than the director of the vaccine center, Tracy Beth Høeg is set to address the audience at the meeting. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth appointee to run the center this calendar year.

Consolidating Power at the Agency

The acting appointment may indicate a closer partnership between the drug and biologics centers as Dr. Høeg and Prasad consolidate power at the FDA – and it suggests a greater focus upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has often pushed for halting some childhood immunization guidelines in the US to become more in line with Denmark, a society with comprehensive healthcare and a population roughly the size of the state of Wisconsin.

In her initial public appearances, she has continued to focus on immunizations – usually the domain of Prasad, director of the FDA’s CBER – instead of medication approval.

Concerns Over Expertise

Høeg has no apparent track record in drug development, oversight or management, which has been standard for past directors of the CBER. She has worked at the FDA as a key advisor to the agency head and CBER since spring.

“It seems she lacks to have the requisite experience” for running the CDER, stated a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She is not versed in managing a sizeable institution. She is not an expert in industry regulation.”

Former commissioners of CBER would “grasp laws and regulations and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Objectively, she doesn’t have the type of experience that previous people who headed the center have had.”

CDER has an immense range of responsibilities at the FDA, she pointed out.

“Many people just focuses on the innovative therapies, but the off-patent medication office clears thousands of generic medications. There’s a biologic copycat branch, over-the-counter program and so forth, and each of these need to be supervised,” she explained. “The area you neglect, that’s the thing that I always told people is going to cause problems.”

Additionally, a significant management component to the role, which manages over 5,000 employees. “It is a massive administrative position, if you do it right,” the former official added.

Agency Reaction and Disputed Policies

Regarding questions about Høeg’s fitness for the role and whether this appointment represents more teamwork among agency officials on immunizations, a representative stated that the “inquiries rely on inaccurate assumptions”.

“This background aligns with the responsibilities of her job,” the representative stated, citing the period Dr. Høeg spent guiding the agency head on “medication safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As acting director, Dr. Høeg inherits the agency head's recently launched fast-track approval initiative, a controversial expedited drug-approval program that allegedly worried her predecessors. “How are these therapies being picked for this voucher program? Who makes the calls?” Howard said. “There’s a lot of secrecy happening at the regulatory body right now.”

In general, he stated, “the agency looks to be trending towards more relaxed regulations of all drugs, aside from immunizations.”

Established Past Work on Vaccines

With vaccines, Dr. Høeg has a more documented, if troubling, past, some experts have noted. She published a study using unverified public submissions to estimate the frequency of myocarditis after Covid immunization. She counseled the Florida chief medical officer Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the incoming federal leadership included altering regulations for novel immunizations and discontinuing “optional” vaccines, she said post-election on a online show. At the agency, Dr. Høeg has according to sources suggested excluding teenage boys from receiving COVID-19 vaccines.

“She is an complete dogmatist who commences with her preconceived notions and works backwards to accommodate the evidence in a highly misleading, fraudulent fashion,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg joined other skeptics, {like|